1h Free Analyst Time
The migraine drugs market in Latin America and it is poised to grow by $82.31 million during 2023-2027, accelerating at a CAGR of 5.82% during the forecast period. The market is driven by the increasing prevalence of migraine in Latin America, the growing number of migraine treatment awareness programs, and drug reformulations.Speak directly to the analyst to clarify any post sales queries you may have.
This report on the migraine drugs market in Latin America provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current regional market scenario, the latest trends and drivers, and the overall market environment.
The migraine drugs market in Latin America is segmented as below:
By End-user
- Hospital
- Retail
- Online
This report on the migraine drugs market in Latin America covers the following areas:
- Migraine drugs market sizing in Latin America
- Migraine drugs market forecast in Latin America
- Migraine drugs market industry analysis in Latin America
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources through an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The analyst's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Therapy
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Executive Summary
The analyst recognizes the following companies as the key players in the global migraine drugs market in Latin America: AbbVie Inc., Amgen Inc., Amneal Pharmaceuticals Inc., Bausch Health Co. Inc., Bayer AG, Daiichi Sankyo Co. Ltd., Dr. Reddys Laboratories Ltd., Eli Lilly and Co., Endo International Plc, Ethypharm SAS, GlaxoSmithKline Plc, H Lundbeck AS, IntelGenx Technologies Corp., Klaria Pharma Holding AB, Kowa Co. Ltd., OptiNose Inc., Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and UCB SA.Commenting on the report, one of the report's analysts said: 'The latest trend gaining momentum in the market is the introduction of new classes of drugs with higher clinical efficacy.'
According to the report, one of the major drivers for this market is the increasing prevalence of migraine in Latin America.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Amgen Inc.
- Amneal Pharmaceuticals Inc.
- Bausch Health Co. Inc.
- Bayer AG
- Daiichi Sankyo Co. Ltd.
- Dr Reddys Laboratories Ltd.
- Eli Lilly and Co.
- Endo International Plc
- Ethypharm SAS
- GlaxoSmithKline Plc
- H Lundbeck AS
- IntelGenx Technologies Corp.
- Klaria Pharma Holding AB
- Kowa Co. Ltd.
- OptiNose Inc.
- Pfizer Inc.
- Sanofi SA
- Teva Pharmaceutical Industries Ltd.
- UCB SA
